Cargando…

Performance of the VitaPCR rapid molecular test for SARS-CoV-2 screening at hospital admission

OBJECTIVE: To evaluate the diagnostic accuracy of rapid VitaPCR™ (Credo) assay as screening test in emergency department (ED) patients prior to transfer or medical interventions. METHODS: In this prospective study 6642 oropharyngeal swabs from nonpreselected ED patients were tested for SARS-CoV-2 wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuierer, Lukas, Kahn, Maria, Messmann, Helmut, Kling, Elisabeth, Römmele, Christoph, Hoffmann, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154245/
https://www.ncbi.nlm.nih.gov/pubmed/37224607
http://dx.doi.org/10.1016/j.diagmicrobio.2023.115974
_version_ 1785036086477586432
author Schuierer, Lukas
Kahn, Maria
Messmann, Helmut
Kling, Elisabeth
Römmele, Christoph
Hoffmann, Reinhard
author_facet Schuierer, Lukas
Kahn, Maria
Messmann, Helmut
Kling, Elisabeth
Römmele, Christoph
Hoffmann, Reinhard
author_sort Schuierer, Lukas
collection PubMed
description OBJECTIVE: To evaluate the diagnostic accuracy of rapid VitaPCR™ (Credo) assay as screening test in emergency department (ED) patients prior to transfer or medical interventions. METHODS: In this prospective study 6642 oropharyngeal swabs from nonpreselected ED patients were tested for SARS-CoV-2 with (1) extraction-free VitaPCR and (2) extraction-based reference assays (Aptima®, cobas®, Xpert®Xpress). RESULTS: The median TAT of VitaPCR was 47 minutes (IQR: 38–59), while reference assays required 6.2 hours (IQR: 4.4–13.3). VitaPCR's sensitivity, specificity, PPV and NPV was 77.9%, 99.9%, 97.9%, and 98.9% in relation to Hologic Panther TMA; 78.3%, 99.8%, 96.4%, and 98.5% compared to Roche cobas6800 PCR; 71.2%, 99.2%, 94.9%, and 94.3% using Cepheid GeneXpert PCR as reference. CONCLUSION: High-sensitivity testing is needed to limit nosocomial spread and identify asymptomatic COVID-19 patients. However, time advantage of the VitaPCR must be weighed against its significantly lower sensitivity, especially when used in high-risk environments such as hospitals.
format Online
Article
Text
id pubmed-10154245
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-101542452023-05-03 Performance of the VitaPCR rapid molecular test for SARS-CoV-2 screening at hospital admission Schuierer, Lukas Kahn, Maria Messmann, Helmut Kling, Elisabeth Römmele, Christoph Hoffmann, Reinhard Diagn Microbiol Infect Dis Original Article OBJECTIVE: To evaluate the diagnostic accuracy of rapid VitaPCR™ (Credo) assay as screening test in emergency department (ED) patients prior to transfer or medical interventions. METHODS: In this prospective study 6642 oropharyngeal swabs from nonpreselected ED patients were tested for SARS-CoV-2 with (1) extraction-free VitaPCR and (2) extraction-based reference assays (Aptima®, cobas®, Xpert®Xpress). RESULTS: The median TAT of VitaPCR was 47 minutes (IQR: 38–59), while reference assays required 6.2 hours (IQR: 4.4–13.3). VitaPCR's sensitivity, specificity, PPV and NPV was 77.9%, 99.9%, 97.9%, and 98.9% in relation to Hologic Panther TMA; 78.3%, 99.8%, 96.4%, and 98.5% compared to Roche cobas6800 PCR; 71.2%, 99.2%, 94.9%, and 94.3% using Cepheid GeneXpert PCR as reference. CONCLUSION: High-sensitivity testing is needed to limit nosocomial spread and identify asymptomatic COVID-19 patients. However, time advantage of the VitaPCR must be weighed against its significantly lower sensitivity, especially when used in high-risk environments such as hospitals. Elsevier Inc. 2023-08 2023-05-03 /pmc/articles/PMC10154245/ /pubmed/37224607 http://dx.doi.org/10.1016/j.diagmicrobio.2023.115974 Text en © 2023 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Schuierer, Lukas
Kahn, Maria
Messmann, Helmut
Kling, Elisabeth
Römmele, Christoph
Hoffmann, Reinhard
Performance of the VitaPCR rapid molecular test for SARS-CoV-2 screening at hospital admission
title Performance of the VitaPCR rapid molecular test for SARS-CoV-2 screening at hospital admission
title_full Performance of the VitaPCR rapid molecular test for SARS-CoV-2 screening at hospital admission
title_fullStr Performance of the VitaPCR rapid molecular test for SARS-CoV-2 screening at hospital admission
title_full_unstemmed Performance of the VitaPCR rapid molecular test for SARS-CoV-2 screening at hospital admission
title_short Performance of the VitaPCR rapid molecular test for SARS-CoV-2 screening at hospital admission
title_sort performance of the vitapcr rapid molecular test for sars-cov-2 screening at hospital admission
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154245/
https://www.ncbi.nlm.nih.gov/pubmed/37224607
http://dx.doi.org/10.1016/j.diagmicrobio.2023.115974
work_keys_str_mv AT schuiererlukas performanceofthevitapcrrapidmoleculartestforsarscov2screeningathospitaladmission
AT kahnmaria performanceofthevitapcrrapidmoleculartestforsarscov2screeningathospitaladmission
AT messmannhelmut performanceofthevitapcrrapidmoleculartestforsarscov2screeningathospitaladmission
AT klingelisabeth performanceofthevitapcrrapidmoleculartestforsarscov2screeningathospitaladmission
AT rommelechristoph performanceofthevitapcrrapidmoleculartestforsarscov2screeningathospitaladmission
AT hoffmannreinhard performanceofthevitapcrrapidmoleculartestforsarscov2screeningathospitaladmission